Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lepodisiran - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Lepodisiran - Eli Lilly and Company

Alternative Names: DCR-CM2; LP(a)-siRNA - Eli Lilly and Company; LY 3819469

Latest Information Update: 28 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Developer Dicerna Pharmaceuticals; Eli Lilly and Company
  • Class Amides; Amino sugars; Antihyperlipidaemics; Cardiovascular therapies; Drug conjugates; Pyrrolidines; Small interfering RNA
  • Mechanism of Action Lipoprotein A expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Hyperlipoproteinaemia(In volunteers) in Singapore (SC)
  • 05 Mar 2024 Phase-III clinical trials in Hyperlipoproteinaemia in United Kingdom, Taiwan, Slovakia, Puerto Rico, Poland, South Korea, Italy, Israel, Hungary, Greece, France, Czech Republic, Canada, Brazil, Belgium, Austria, Australia, Argentina, Romania, Spain, Japan, Netherlands, Mexico, China, Germany, Denmark, USA (SC) (NCT06292013)
  • 09 Jan 2024 Eli lily and company completes a phase I trial pharmacokinetics trial (In volunteers) in USA (SC) (NCT05841277)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top